

Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1485, 2005-01, pp. : 6-6
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Zoledronic acid, pamidronic acid on equal footing in bone metastases
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 475, 2005-01 ,pp. :


Zoledronic acid beneficial in patients with bone metastases
Inpharma, Vol. 1, Iss. 1292, 2001-01 ,pp. :



